Nuvectis Pharma reports Q2 2026 results; in-licenses two late-stage assets, ciprocopan approved in China, raises $115M

Nuvectis Pharma, Inc.

In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; ciprocopan approved in China for PNH in July 2026.
Completed follow-on offering in July 2026 raising $115M gross proceeds, extending cash runway into 1H 2029.
Cash and equivalents $22.2M as of June 30, 2026, down from $31.6M at Dec 31, 2025.
Net loss for Q2 2026 was $7.0M vs $6.3M in Q2 2025; R&D expenses rose to $4.7M from $3.6M.
U.S. IND submission for ciprocopan expected in 4Q2026; NXP200 IND also expected in 4Q2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.